IPO Boutique

Trevena IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on Trevena, and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
TrevenaTRVN -
NASDAQ
$7.00-$7.00 $7.00 $7.119.3 million1/31/2014
Barclays, Jefferies
Co-Manager(s):
Canaccord Genuity, JMP Securities, Needham & Co.
Health Care
Filing(s):

Filed 2013-10-09
New Terms Added 2014-01-29



Trevena Quote & Chart - Click for current quote - TRVN

About Trevena (adapted from Trevena prospectus):
They are a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as "TRVN" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved